CSL anticipates robust annualized double-digit earnings grow...
CSL anticipates robust annualized double-digit earnings growth over the medium term, driven by strong patient demand for its immunoglobulins franchise. The company has bounced back from the pandemic's impact on its blood plasma collections.
![](https://usnewsfile.moomoo.com/news-thumbnail/20240213/public/17078073276981895922924.jpeg)
Disclaimer: The above information does not represent the views of Moomoo Technologies Inc. (MTI) or constitute investment advice related to MTI and its affiliates.
Read more
Comment
Sign in to post a comment